{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:27:42Z","timestamp":1788218862291,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen"},{"DOI":"10.13039\/100011093","name":"Shire Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010230","name":"Department of Health, Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There is scant data on the role of hyperuricaemia, gout and allopurinol treatment in chronic kidney disease (CKD). Therefore, our aim is to investigate the possible associations between hyperuricaemia, gout, prescription of allopurinol and renal outcomes in patients with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The retrospective cohort study involved 1123 Royal Brisbane and Women\u2019s Hospital (RBWH) patients, enrolled in the CKD.QLD registry from May 2011 to August 2017. Patients were divided into two uric acid categories, with uric acid\u2009\u2264\u20090.36\u00a0mmol\/L and\u2009&gt;\u20090.36\u00a0mmol\/L. Association of delta estimated glomerular filtration rate (eGFR) with gout, allopurinol treatment and hyperuricaemia were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients with an entry urate\u2009&gt;\u20090.36\u00a0mmol\/L were older, had higher body mass index (BMI) and worse baseline kidney function. Proportion of patients with gout, hyperuricaemia and allopurinol treatment increased with advanced CKD stages. Age-adjusted analysis revealed a significant association between serum urate level and delta eGFR, with no significant association between gout, treatment with\u00a0allopurinol and delta eGFR. Furthermore, neither gout nor the prescription of allopurinol had a significant effect on the time to renal death (composite end point of kidney replacement therapy or death).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Hyperuricaemia seemed to be independently associated with faster CKD progression or renal death. This was not observed with gout or prescription of allopurinol. Furthermore, allopurinol was not associated with decreased incidence of\u00a0cardiovascular events. These data suggest that hyperuricaemia is likely the effect and not the cause of CKD\u00a0or CKD progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-020-00937-4","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T21:40:10Z","timestamp":1610574010000},"page":"753-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hyperuricaemia, gout and allopurinol in the CKD Queensland registry"],"prefix":"10.1093","volume":"34","author":[{"given":"A.","family":"Jeyaruban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"issue":"3","key":"937_CR1","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.ki.5002343","volume":"72","author":"AS Levey","year":"2007","unstructured":"Levey AS, Atkins R, Coresh J, Cohen EP, Collins AJ, Eckardt KU et al (2007) Chronic kidney disease as a global public health problem: approaches and initiatives\u2014a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 72(3):247\u2013259","journal-title":"Kidney Int"},{"issue":"6","key":"937_CR2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.113.007106","volume":"130","author":"M Sud","year":"2014","unstructured":"Sud M, Tangri N, Pintilie M, Levey AS, Naimark D (2014) Risk of end-stage renal disease and death after cardiovascular events in chronic kidney disease. Circulation 130(6):458\u2013465","journal-title":"Circulation"},{"issue":"9889","key":"937_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 382(9889):339\u2013352","journal-title":"Lancet"},{"key":"937_CR4","first-page":"151","volume":"5","author":"L Braun","year":"2012","unstructured":"Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C (2012) High burden and unmet patient needs in chronic kidney disease. Int J NephrolRenovasc Dis 5:151\u2013163","journal-title":"Int J NephrolRenovasc Dis"},{"issue":"3","key":"937_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000331453","volume":"35","author":"Y Shi","year":"2012","unstructured":"Shi Y, Chen W, Jalal D, Li Z, Chen W, Mao H et al (2012) Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. Kidney Blood Press Res 35(3):153\u2013160","journal-title":"Kidney Blood Press Res"},{"issue":"12","key":"937_CR6","first-page":"2888","volume":"13","author":"DH Kang","year":"2002","unstructured":"Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M et al (2002) A role for uric acid in the progression of renal disease. J Am SocNephrol 13(12):2888\u20132897","journal-title":"J Am SocNephrol"},{"issue":"6","key":"937_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1291\/hypres.24.691","volume":"24","author":"K Iseki","year":"2001","unstructured":"Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S (2001) Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res 24(6):691\u2013697","journal-title":"Hypertens Res"},{"issue":"4","key":"937_CR8","doi-asserted-by":"publisher","first-page":"F1134","DOI":"10.1152\/ajprenal.00104.2008","volume":"295","author":"LG Sanchez-Lozada","year":"2008","unstructured":"Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T et al (2008) Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 295(4):F1134\u2013F1141","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"937_CR9","doi-asserted-by":"publisher","first-page":"F1238","DOI":"10.1152\/ajprenal.00164.2006","volume":"292","author":"LG Sanchez-Lozada","year":"2007","unstructured":"Sanchez-Lozada LG, Tapia E, Lopez-Molina R, Nepomuceno T, Soto V, Avila-Casado C et al (2007) Effects of acute and chronic l-arginine treatment in experimental hyperuricemia. Am J Physiol Renal Physiol 292(4):F1238\u2013F1244","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"937_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","volume":"67","author":"LG Sanchez-Lozada","year":"2005","unstructured":"Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T et al (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67(1):237\u2013247","journal-title":"Kidney Int"},{"issue":"5","key":"937_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1053\/j.ajkd.2008.12.021","volume":"53","author":"M Madero","year":"2009","unstructured":"Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW et al (2009) Uric acid and long-term outcomes in CKD. Am J Kidney Dis 53(5):796\u2013803","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"937_CR12","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/01.CIR.0000046448.26751.58","volume":"107","author":"S Guthikonda","year":"2003","unstructured":"Guthikonda S, Sinkey C, Barenz T, Haynes WG (2003) Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 107(3):416\u2013421","journal-title":"Circulation"},{"issue":"8","key":"937_CR13","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2215\/CJN.01580210","volume":"5","author":"M Goicoechea","year":"2010","unstructured":"Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincon A et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am SocNephrol 5(8):1388\u20131393","journal-title":"Clin J Am SocNephrol"},{"issue":"1","key":"937_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51\u201359","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"937_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12882-017-0607-5","volume":"18","author":"SK Venuthurupalli","year":"2017","unstructured":"Venuthurupalli SK, Hoy WE, Healy HG, Cameron A, Fassett RG (2017) CKD.QLD: establishment of a chronic kidney disease [CKD] registry in Queensland, Australia. BMC Nephrol 18(1):189","journal-title":"BMC Nephrol"},{"issue":"1","key":"937_CR16","doi-asserted-by":"publisher","first-page":"e0170393","DOI":"10.1371\/journal.pone.0170393","volume":"12","author":"CW Tsai","year":"2017","unstructured":"Tsai CW, Lin SY, Kuo CC, Huang CC (2017) Serum uric acid and progression of kidney disease: a longitudinal analysis and mini-review. PLoS ONE 12(1):e0170393","journal-title":"PLoS ONE"},{"key":"937_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12882-015-0047-z","volume":"16","author":"T Kanji","year":"2015","unstructured":"Kanji T, Gandhi M, Clase CM, Yang R (2015) Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol 16:58","journal-title":"BMC Nephrol"},{"issue":"26","key":"937_CR18","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","volume":"382","author":"SV Badve","year":"2020","unstructured":"Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A et al (2020) Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med 382(26):2504\u20132513","journal-title":"N Engl J Med"},{"issue":"8","key":"937_CR19","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.2337\/dc19-0342","volume":"42","author":"M Afkarian","year":"2019","unstructured":"Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ et al (2019) Preventing early renal loss in diabetes (PERL) study: a randomized double-blinded trial of allopurinol-rationale, design, and baseline data. Diabetes Care 42(8):1454\u20131463","journal-title":"Diabetes Care"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-020-00937-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-020-00937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:37Z","timestamp":1777564537000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/34\/3\/753\/8325980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1007\/s40620-020-00937-4","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"21 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Our study does not include any studies with human participants done by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}